Oncorus, Inc.
Cambridge, MA · Founded 2015 · CIK 0001671818 · Biotech · Defunct
Engineered oncolytic herpes simplex virus armed with immunostimulatory transgenes for intratumoral GBM treatment
oncorus.com →- Grants
- $300K
- 1 award
- Sector median: 1
- Raised
- $47M
- 2 Form D · Aug 2019
- 86 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 5 granted · 35 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $4,612,500 | |
| Private capital raised | Form D · SEC | $42,123,626 | |
| Federal grant | Department of Health and Human Services · Phase I · Design of a micro-RNA attenuated armed oHSV for the treatment of glioblastoma | $299,976 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1199 | AIMMAX THERAPEUTICS INC | — | $200K |
| 1200 | DMC BIOTECHNOLOGIES, INC. | — | $47M |
| 1201 | Obatala Sciences, Inc. | — | $200K |
| 1202 | Oncorus, Inc. | — | $47M |
| 1203 | Qlaris Bio, Inc. | — | $42M |
| 1204 | PLAKOUS THERAPEUTICS, INC. | — | $185K |
| 1205 | ADIAL PHARMACEUTICALS, INC. | — | $38M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Theodore AshburnDirector · Executive Officer
- Thomas ChalbergExecutive Officer
- Luke EvninDirector
- Mary Kay FentonDirector
- Mitchell FinerDirector · Executive Officer
- Robert KirkmanDirector
- Alon LazarusDirector
- John McCabeExecutive Officer
- Briggs MorrisonDirector
- Cyrus MozayeniExecutive Officer
- Spencer NamDirector
- Christophe QuevaExecutive Officer
- Marc RechtExecutive Officer
- Cameron WheelerDirector
Patents
- Oncolytic Viral Vectors And Uses Thereofgranted
- Oncolytic Viral Vectors And Uses Thereofgranted
- Oncolytic Viral Delivery Of Therapeutic Polypeptidesgranted
- Encapsulated Polynucleotides And Methods Of Useapplication
- Oncolytic Viral Delivery Of Therapeutic Polypeptidesgranted
- Oncolytic Viral Vectors And Uses Thereofgranted
- Pseudotyped Oncolytic Viral Delivery Of Therapeutic Polypeptidesapplication
- Oncolytic Viral Vectors Encoding Therapeutic Polypeptides And Uses Thereofapplication
- Encapsulated Rna Replicons And Methods Of Useapplication
- ANTI-DLL3 Antibodies And Methods Of Useapplication
- Lipid Nanoparticle Compositions And Methods Of Using Thereofapplication
- Lipid Nanoparticle Compositions And Methods Of Using Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.